Hormone therapy, radiotherapy, and risk for cardiovascular mortality

An article in this week’s Journal of the American Medical Association has gained a great deal of media attention because it links hormone therapy in prostate cancer patients to a risk for death in patients with pre-existing cardiovascular disorders. The “New” Prostate Cancer InfoLink feels that it should emphasize that the outcomes reported in this study are actually not surprising at all. The risk of cardiovascular mortality associated with hormone therapy in men with prostate cancer  is well known and well understood. What is surprising to us is that these men were ever exposed to hormone therapy under the circumstances described! … READ MORE …

Prostate cancer news reports: Thursday, July 16, 2009

Today’s news reports include items on:

  • Exercise and prostate cancer risk (in mice)
  • Quality of life over 4 years after first-line therapy
  • The adverse effects of long-term hormone therapy … READ MORE …

Prostate cancer news reports: Sunday, July 12, 2009

This weekend’s news reports deal with:

  • A new epidemiological database for prostate cancer research
  • Phase II trial results for the “vaccine” PSA: 154-163 (155L)
  • The degree to which adding hormone therapy to radiotherapy affects outcomes in patients with localized prostate cancer
  • The possibility that zoledronic acid could be used just once a year to prevent bone loss and related events in men having androgen deprivation therapy … READ MORE …

Prostate cancer news reports: Friday, June 12, 2009

Todays news reports adddress:

  • Surgeon and hospital volume and outcomes to radical prostatectomy
  • Adverse events associated with the use of hypofractionated, dose-escalated, IMRT
  • Quality of sexual function after external beam radiation therapy
  • Percentage of positive biopsy cores and response to first-line hormone therapy … READ MORE …

Prostate cancer news reports: Thursday, June 11, 2009

Today’s prostate cancer news report deals with:

  • A recent review of appropriate penile rehabilitation strategies
  • Management of biochemical recurrence after first-line treatment failure
  • Initial use of hormone therapy by French clinicians … READ MORE …

Hormone therapy and radiation treatment: a topical update

There are several recent reports that address factors specific to the combination of hormone therapy with radiation therapy in the management of prostate cancer, so we thought it would be helpful to offer a topical update. … READ MORE …

Prostate cancer news reports: Thursday, May 21, 2009

Today’s news reports cover items on:

  • “Elastography” in assessment of risk of prostate cancer
  • Ejaculatory function before and after brachytherapy
  • Hormone therapy for prostate cancer: a 20-year, single institution experience … READ MORE …

AUA report and update no. 6: Monday, April 27, 2009

We learned a few other interesting tidbits during a variety of sessions and conversations today. … READ MORE …

Tuesday’s news reports: March 24, 2009

Comment on an article on PSA velocity and prediction of biopsy outcomes has been provided separately. Today’s other news includes reports on:

  • Pathological outcomes and criteria for active surveillance protocols
  • Outcomes to permanent seed implant brachytherapy: age does not affect outcome
  • Vacuum erectile devices and their value in post-prostatectomy erectile dysfunction
  • Biochemical recurrence post-prostatectomy and the role of hormone therapy … READ MORE …

The Thursday news reports: March 19, 2009

There are six new reports in today’s news, of which the most immediately important would seem to be:

  • How men manage their “fear” while on active surveillance
  • “Cancer anxiety” and early use of hormonal therapy
  • Approval for a Phase III clinical trial of MDV3100 … READ MORE …

Anxiety predicts early use of hormone therapy

It is well known to readers of The “New” Prostate Cancer InfoLink that androgen deprivation therapy (ADT) is a commonly used form of treatment for patients who experience biochemical recurrence (BCR) after first- or second-line therapy. However, as is also well known, the optimal timing of ADT initiation is uncertain, and earlier initiation of ADT can cause toxicities that lower patients’ health-related quality of life (HRQOL). … READ MORE …

Watchful waiting, hormone therapy, and quality of life

McDermott and Sanda have just published an assessment of the recent re-analysis of the Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4).  This is the study that initially demonstrated a modest but significant survival benefit of prostatectomy over watchful waiting.

According to the re-analysis of this study, patients allocated to watchful waiting experienced a significantly decreased health-related quality of life (HRQOL) at 6–8 years after randomization, compared with those who underwent radical prostatectomy. … READ MORE …

Hormone therapy + radiotherapy as first-line treatment: how long do you need hormones?

Here’s a question that comes up over and over again from newly diagnosed patients: “My doctor is suggesting I get hormones in  combination with radiation therapy. How long am I likely to be on hormone therapy?” … READ MORE …

Hormone therapy with and without radiotherapy in high-risk, localized prostate cancer

In September this year, writing from the 50th annual meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), Dr. Eyad Abu-Isa addressed breaking news of a Scandinavian trial comparing radiotherapy + hormone therapy to radiotherapy alone in the treatment of locally advanced prostate cancer. The complete results of this study in were just published in The Lancet . … READ MORE …

Neoadjuvant hormone therapy in localized and locally advanced prostate cancer

The Cochrane Collaboration is a highly respected global network that seeks to improve healthcare decision-making through systematic reviews of the effects of healthcare interventions, published in The Cochrane Library. The Cochrane Urological Cancers Unit has just published a detailed review and assessment of the value of hormone therapy in neoadjuvant management of localized and locally advanced prostate cancer. … READ MORE …